Kovitz Investment Group Partners LLC Acquires 9,093 Shares of Edwards Lifesciences Co. (NYSE:EW)

Kovitz Investment Group Partners LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 65.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,039 shares of the medical research company's stock after purchasing an additional 9,093 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in Edwards Lifesciences were worth $1,520,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in EW. Wedgewood Partners Inc. grew its stake in shares of Edwards Lifesciences by 1.4% during the third quarter. Wedgewood Partners Inc. now owns 359,257 shares of the medical research company's stock valued at $23,898,000 after purchasing an additional 4,830 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after buying an additional 14,610,123 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $39,628,000. Wahed Invest LLC increased its stake in shares of Edwards Lifesciences by 9.9% in the 3rd quarter. Wahed Invest LLC now owns 14,517 shares of the medical research company's stock valued at $958,000 after buying an additional 1,308 shares during the period. Finally, Soros Fund Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth $19,797,000. Institutional investors own 79.46% of the company's stock.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock worth $2,323,150 over the last ninety days. Insiders own 1.27% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on EW shares. Sanford C. Bernstein upgraded Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a research report on Thursday, December 5th. Truist Financial restated a "hold" rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Morgan Stanley reaffirmed an "equal weight" rating and set a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Oppenheimer reissued an "outperform" rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $78.65.

Edwards Lifesciences Stock Up 0.5 %

NYSE EW traded up $0.39 on Wednesday, reaching $73.78. The company had a trading volume of 3,593,751 shares, compared to its average volume of 4,652,855. The company's fifty day moving average is $68.92 and its 200-day moving average is $74.19. The firm has a market capitalization of $43.52 billion, a price-to-earnings ratio of 10.60, a price-to-earnings-growth ratio of 3.52 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. Edwards Lifesciences's revenue for the quarter was up 8.9% compared to the same quarter last year. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.